ClinicalTrials.gg
RecruitingNCT05327894Interfant-21Updated Oct 19, 2026

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

A Phase 3 interventional study of Blinatumomab and Blinatumomab in Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, sponsored by Princess Maxima Center for Pediatric Oncology. Recruiting at 124 sites in 24 countries. Open to participants aged 1 Day to 1 Year. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Princess Maxima Center for Pediatric Oncology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Oct 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
1 Day to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
18th of 61
160 · median 67
Started
2022
with 1 other
Phase 3
11 of 61
4 open now
Primary completion
2027-09
later than 20 of 38 live
Registered
42nd of 61
by date

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 18th largest by planned enrollment, is one of 2 that started in 2022, is one of 11 in phase 3, reaches primary completion later than 20 of the 38 other live ones, and was the 42nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Day to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.

Read the detailed description

All infants that are eligible for this study and for whom the parents/legal representatives give informed consent will be enrolled in this study. All patients will receive one cycle of blinatumomab on top of the standard treatment backbone after induction therapy. Medium risk patients, that respond well to the 1st cycle will be treated with a 2nd cycle of blinatumomab replacing one chemo course after consolidation therapy. If they do not respond well enough they will be treated according to the current treatment standard. Minimal residual disease will be used to determine the response to blinatumomab. High risk patients will be eligible for allogeneic stem cell transplantation after the first blinatumomab cycle if they are Minimal Residual Disease (MRD) negative (defined as \< 0.01%). Also medium risk patients with insufficient MRD response after induction or after the 1st cycle of blinatumomab will be allocated to high risk treatment and will be eligible for allogeneic stem cell transplantation.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Mixed Phenotype Acute Leukemia

Keywords

  • infant under one year
  • KMT2A-wildtype
04

Who can participate

Ages eligible
1 Day to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with newly diagnosed B- precursor ALL or B-cell MPAL (single lineage) according to the WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition 2017), with KMT2A-rearrangement.
  2. ≤ 365 days of age at the time of diagnosis of ALL.
  3. Written of the parent(s) or other legally authorized guardian of the patient according to local law and regulations.

Exclusion criteria

Exclusion criteria for blinatumomab:

  1. KMT2A-wildtype patients.
  2. Multilineage MPAL
  3. T-ALL.
  4. Age > 365 days at the time of diagnosis.
  5. Down syndrome.
  6. ALL.
  7. Treatment with systemic (equivalent prednisone >10 mg/m2/day) for more than one week and/or any chemotherapeutic agent in the 4-week interval prior to diagnosis. Patients who received corticosteroids by aerosol are eligible for the study.

If exclusion criteria for blinatumomab are met, the patient should be treated according to the protocol but without blinatumomab.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Other
    Medium Risk (MR)

    Subject is defined as MR if \> 6months of age at diagnosis, OR \< 6 months of age with White Blood cell Count (WBC) \< 300 at diagnosis and good prednisone response. Subject gets 1st cycle of blinatumomab. If MRD is \>0.01%, after 1st cycle of blinatumomab, subject will be allocated to HR treatment from that phase, and will be eligible for HSCT. If MRD is undetectable or \< 0.01% after the 1st cycle of blinatumomab (TP2) patient will be eligible for replacement of MARMA by 2nd cycle of blinatumomab after receipt of lymphoid style consolidation (Protocol IB) or of myeloid style consolidation (ADE/MAE).

    Drug: Blinatumomab

  • Other
    High risk (HR)

    Subject is defined as HR if \< 6 months of age with WBC \> 300 at diagnosis OR poor prednisone response. Also MR patients with end of induction MRD ≥ 1%, or MRD \> 0.01% after the 1st cycle of blinatumomab, will be allocated to HR treatment. Subject gets 1 cycle of blinatumomab. Thereafter patient is eligible for hematopoietic stem cell transplantation (HSCT) with or without experimental therapy in an investigational window.

    Drug: Blinatumomab

Interventions

  • 1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.

    Also known as: Cycle 1

  • 2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion

    Also known as: Cycle 2

06

What researchers measure

Primary outcomes

  1. Event free survival (EFS).

    The primary endpoint is EFS, defined as the time from diagnosis to resistance to induction, relapse, death from any cause or second malignancy (whichever occurs first), or time to last follow-up (censored) for patients without events.

    Time frame: 5 years

Secondary outcomes

  1. Overall survival

    The endpoints for analysis by risk group will be EFS, cumulative incidence (or percentage) of resistance to induction, cumulative incidence of relapse (CIR), death in complete remission (CR) and second malignancy.

    Time frame: 8 years

  2. Endpoints by risk group

    The endpoints for analysis by risk group will be EFS, cumulative incidence (or percentage) of resistance to induction, cumulative incidence of relapse (CIR), death in complete remission (CR) and second malignancy.

    Time frame: 8 years

  3. Outcome for the entire study cohort and according to risk group

    Outcome for the entire study cohort and according to risk group will be evaluated in terms of the protocol specific definition of EFS follows: the time from diagnosis to, resistance to proto-col, relapse, death from any cause or second malignancy (whichever occurs first), or time to last follow-up for patients without events. Cumulative incidence (or percentage) of resistance, CIR, death in CR and second malignancy will also be estimated.

    Time frame: 8 years

  4. Minimal Residual Disease

    MRD response as defined in the protocol and frequencies of MRD levels

    Time frame: 8 years

  5. CD19 (cluster of differentiation antigen 19) negative relapse

    Proportion of CD19 negative relapses in the entire study cohort and according to risk group

    Time frame: 8 years

  6. Myeloid lineage switches

    Proportion of myeloid lineage switches in the entire study cohort and according to risk group

    Time frame: 8 years

  7. Grade ≥3 adverse event

    Proportion of grade ≥3 adverse event (AEs) during the blinatumomab course(s). Proportion of adverse events of special interest (AESIs) and serious adverse events (SAEs) in all protocol phases.

    Time frame: 8 years

  8. Grade ≥2 cardiac disorders

    Proportion of grade ≥2 cardiac disorders at 2 and 5 years after diagnosis

    Time frame: 5 years

  9. Overall survival after 1st relapse

    Overall survival (OS) after first relapse, defined as the time from first relapse to death from any cause, in the entire study cohort and according to risk group

    Time frame: 8 years

07

Study locations

101 of 124 sites recruiting

Showing the first 100 of 124 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463 ↗

Individual participant data

Plan to share: Yes — all individual participant data that underlie results in a publication

Supporting information: Clinical study report

Time frame: The Clinical Study Report (CSR) will be made available within 6 months upon study end.

Access criteria: A summary of the study results will be made public via www.clinical trials.gov as well as to Ethical committees/ Health Authorities and all participating patients by providing them through their treating physicians a patient letter with a summary of the results.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Sep 2027, 57 months after the start.

Of 43 non-industry phase 3 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 109. This study's planned 57 months is below that.

Counting every sponsor, half of 59 studies reached it within 86 months; a quarter within 46 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Dec 15, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites changed recruiting status (9 now recruiting)
Show 9 sites
  • Cliniques Universitaires Saint-Luc · Brussels, BelgiumActive, not recruiting→Recruiting
  • CHU Besancon · Besançon, FranceActive, not recruiting→Recruiting
  • CHRU de Lille · Lille, FranceActive, not recruiting→Recruiting
  • Hokkaido University Hospital · Hokkaido, JapanActive, not recruiting→Recruiting
  • Hyogo Prefectural Kobe Childrens Hospital · Hyōgo, JapanActive, not recruiting→Recruiting
  • Tohoku University Hospital · Tōhoku, JapanActive, not recruiting→Recruiting
  • Haukeland University Hospital · Bergen, NorwayActive, not recruiting→Recruiting
  • King Abdulaziz Medical City, King Abdullah International Medical Research Center · Riyadh, Saudi ArabiaActive, not recruiting→Recruiting
  • National Institute of Children's Diseases · Bratislava, SlovakiaActive, not recruiting→Recruiting
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Cliniques Universitaires Saint-Luc · Brussels, BelgiumActive, not recruiting→Recruiting
    • CHU Besancon · Besançon, FranceActive, not recruiting→Recruiting
    • CHRU de Lille · Lille, FranceActive, not recruiting→Recruiting
    • Hokkaido University Hospital · Hokkaido, JapanActive, not recruiting→Recruiting
    • Hyogo Prefectural Kobe Childrens Hospital · Hyōgo, JapanActive, not recruiting→Recruiting
    • Tohoku University Hospital · Tōhoku, JapanActive, not recruiting→Recruiting
    • Haukeland University Hospital · Bergen, NorwayActive, not recruiting→Recruiting
    • King Abdulaziz Medical City, King Abdullah International Medical Research Center · Riyadh, Saudi ArabiaActive, not recruiting→Recruiting
    • National Institute of Children's Diseases · Bratislava, SlovakiaActive, not recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05327894
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Collaborators
University of Milano Bicocca, Amgen Europe B.V
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Dec 15, 2022
Primary completion
Sep 2027 (estimated)
Completion
Sep 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Lieke van den Wildenberg
Contact
trialmanagement@prinsesmaximacentrum.nl
0031 88 972 72 72
Peggy Scholte-Van Houtem
Contact
trialmanagement@prinsesmaximacentrum.nl
0031 88 972 72 72
Janine Stutterheim, Dr
principal investigator · Princess Maxima Center for Pediatric Oncology in The Netherlands

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion